An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistance

STAR Protoc. 2021 Apr 8;2(2):100460. doi: 10.1016/j.xpro.2021.100460. eCollection 2021 Jun 18.

Abstract

Previously, we identified a therapy-resistant role of IL-34 in an immune checkpoint blockade in murine models. To investigate whether a similar mechanism is applicable in human tumors as well, we used this protocol for the selection of IL-34-neutralizing antibody and transplanting human tumor tissue expressing both IL-34 and PD-L1 as a patient-derived xenograft in immunologically humanized mice. This model helps to determine the effect of IL-34 neutralization along with the immune checkpoint blockade in human tumors. For complete details on the use and execution of this protocol, please refer to Hama et al. (2020).

Keywords: Antibody; Cancer; Cell culture; Immunology; Model Organisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing* / immunology
  • Antibodies, Neutralizing* / pharmacology
  • B7-H1 Antigen / immunology*
  • Heterografts
  • Humans
  • Interleukins* / antagonists & inhibitors
  • Interleukins* / immunology
  • Mice
  • Models, Immunological*
  • Tissue Transplantation*

Substances

  • Antibodies, Neutralizing
  • B7-H1 Antigen
  • IL34 protein, human
  • Interleukins